佩拉卡森:作用机制和Lp (a) 降低作用
Harpreet S Bhatia1, Archna Bajaj2, Sascha N Goonewardena3
1Division of Cardiovascular Medicine, University of California San Diego, San Diego, CA, USA (Dr Bhatia).
Journal of clinical lipidology
|August 8, 2025
概括
佩拉卡森是一种反感性寡核酸,通过向apoa生产,显著降低脂蛋白 (Lp[a]) 水平. 这种试验性疗法在患有升高Lp (a) 的患者中,有望控制动脉样硬化心血管疾病风险.
科学领域:
- 生物化学 生物化学
- 遗传学 是一个遗传学.
- 心脏病学 心脏病学
背景情况:
- 脂蛋白a (Lp[a]) 是动脉样硬化心血管疾病 (ASCVD) 的遗传决定性风险因素,影响全球超过14亿人.
- 升高的Lp(a) 水平 (≥125nmol/L) 与促炎,促血栓和促动脉的机制有关.
- 目前的药物治疗提供有限的Lp(a) 降低效果,在美国没有经批准的治疗方法,尽管在特定情况下,非是一种选择.
研究的目的:
- 审查研究中的RNA向药物佩拉卡森的作用机制.
- 为佩拉卡森降低Lp (a) 的效果提供证据.
- 为了突出正在进行的第3阶段Lp(a) HORIZON研究,评估心血管事件减少.
主要方法:
- 佩拉卡森是一种第二代反感性寡核酸 (ASO),旨在准阿波利波蛋白 (apo[a]) 生产.
- 它利用化学修饰,包括N-乙银胺,以提高生物稳定性和肝细胞吸收.
- 一项2b期研究评估了佩拉卡森在已确诊的ASCVD患者中的疗效和安全性.
主要成果:
- 佩拉卡森在2b期研究中显示,Lp (a) 度显著降低了80%以上.
- 该疗法在已确诊的ASCVD患者中表现出良好的安全性.
- 现有的治疗方法,如PCSK9抑制剂,对Lp (a) 水平仅有适度的影响.
结论:
- 佩拉卡森有效降低Lp (a) 水平,提供了潜在的新治疗策略.
- 目前正在进行的第3期Lp(a) HORIZON研究将确定这些Lp(a) 降低效应是否转化为减少心血管事件.
- 针对RNA的疗法代表了管理与Lp(a) 相关的心血管风险的有希望的途径.
更多相关视频
09:15Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
14.7K
11:00A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium
Published on: June 22, 2010
28.9K
相关概念视频
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
603
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
603
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
871
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
871
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
225
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
225
01:23Local Anesthetics: Mechanism of Action
2.5K
Local anesthetics (LAs) block sensory and motor impulses by inhibiting the sodium channels on the nerve cell membranes. This induces temporary loss of sensation, relieving pain in a specific body area.
Local anesthetics are amphiphilic molecules consisting of a hydrophobic aromatic part linked to a hydrophilic group by an ester or amide linkage. They are weak bases and are usually available as salts, which increases their solubility and stability. Once administered, LAs exist in the body either...
Local anesthetics are amphiphilic molecules consisting of a hydrophobic aromatic part linked to a hydrophilic group by an ester or amide linkage. They are weak bases and are usually available as salts, which increases their solubility and stability. Once administered, LAs exist in the body either...
2.5K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
680
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
680
01:13Local Anesthetics: Pharmacokinetics
851
The potency and duration of action of local anesthetics (LAs) are determined by their pharmacokinetics. Pharmacokinetics describes how LAs are absorbed, distributed, metabolized, and eliminated from the body. When administered to the vascular tissues, LAs are quickly absorbed and enter the systemic circulation, reducing their localized effects. Adding vasoconstrictors such as epinephrine to LAs reduces their absorption into the systemic circulation, making them clinically effective. The...
851